The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 03, 2015

Filed:

Apr. 19, 2011
Applicants:

Hiroko Hanzawa, Tokorozawa, JP;

Takeshi Sakamoto, Asaka, JP;

Naomi Manri, Kawagoe, JP;

Yuji Kuge, Sapporo, JP;

Inventors:

Hiroko Hanzawa, Tokorozawa, JP;

Takeshi Sakamoto, Asaka, JP;

Naomi Manri, Kawagoe, JP;

Yuji Kuge, Sapporo, JP;

Assignee:

Hitachi, Ltd., Tokyo, JP;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
G01N 31/00 (2006.01); G01N 33/53 (2006.01); C12Q 1/68 (2006.01); G01N 33/564 (2006.01); G01N 33/86 (2006.01); G01N 33/18 (2006.01);
U.S. Cl.
CPC ...
C12Q 1/6883 (2013.01); G01N 33/1826 (2013.01); G01N 33/564 (2013.01); G01N 33/86 (2013.01); C12Q 2600/112 (2013.01); C12Q 2600/158 (2013.01); G01N 33/18 (2013.01); G01N 2333/4716 (2013.01); G01N 2800/323 (2013.01); G01N 2800/50 (2013.01); G01N 2800/52 (2013.01);
Abstract

Arteriosclerosis induces cerebral infarction and myocardial infarction. A multi-marker (a group of protein markers) that assesses the accurate pathogenesis of arteriosclerosis and enables the selection of an adequate treatment method for arteriosclerosis and prediction of the progression of arteriosclerosis, and an evaluation method for the diagnosis, prevention, and treatment of arteriosclerosis that uses said marker group as an indicator have been sought. The present invention relates to A method for evaluation of arteriosclerosis comprising the steps of (a) measuring the expression of von Willebrand factor and/or complement factor D in a sample derived from a subject, (b) measuring the expression of complement component C8 and/or vitamin K-dependent protein Z in the sample derived from the subject, and (c) evaluating arteriosclerosis in the subject on the basis of the results from (a) and (b).


Find Patent Forward Citations

Loading…